These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31952572)

  • 21. Flavonoids Overcome Drug Resistance to Cancer Chemotherapy by Epigenetically Modulating Multiple Mechanisms.
    To KKW; Cho WCS
    Curr Cancer Drug Targets; 2021; 21(4):289-305. PubMed ID: 33535954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy.
    Castilho RM; Squarize CH; Almeida LO
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28704968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance.
    Li GH; Qu Q; Qi TT; Teng XQ; Zhu HH; Wang JJ; Lu Q; Qu J
    J Exp Clin Cancer Res; 2021 May; 40(1):174. PubMed ID: 34011395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators.
    Rauscher S; Greil R; Geisberger R
    Curr Cancer Drug Targets; 2021; 21(4):353-359. PubMed ID: 33423645
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting components of epigenome by small molecules.
    You JS; Han JH
    Arch Pharm Res; 2014 Nov; 37(11):1367-74. PubMed ID: 25070764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Towards a more precise therapy in cancer: Exploring epigenetic complexity.
    Cossío FP; Esteller M; Berdasco M
    Curr Opin Chem Biol; 2020 Aug; 57():41-49. PubMed ID: 32480315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance.
    Trimarchi MP; Mouangsavanh M; Huang TH
    Chin J Cancer; 2011 Nov; 30(11):749-56. PubMed ID: 22035855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic perspectives on cancer chemotherapy response.
    Liu MZ; McLeod HL; He FZ; Chen XP; Zhou HH; Shu Y; Zhang W
    Pharmacogenomics; 2014 Apr; 15(5):699-715. PubMed ID: 24798726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Epigenetics for the Efficacy of Cisplatin.
    Lumpp T; Stößer S; Fischer F; Hartwig A; Köberle B
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic agents in combined anticancer therapy.
    Kejík Z; Jakubek M; Kaplánek R; Králová J; Mikula I; Martásek P; Král V
    Future Med Chem; 2018 May; 10(9):1113-1130. PubMed ID: 29676175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic Drug Therapy in the Treatment of Colorectal Cancer.
    Parizadeh SM; Jafarzadeh-Esfehani R; Ghandehari M; Seifi S; Parizadeh SMR; Moetamani-Ahmadi M; Hassanian SM; Khazaei M; Ghayour-Mobarhan M; Ferns GA; Avan A
    Curr Pharm Des; 2018; 24(23):2701-2709. PubMed ID: 30062956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic reprogramming in breast cancer: from new targets to new therapies.
    Katz TA; Huang Y; Davidson NE; Jankowitz RC
    Ann Med; 2014 Sep; 46(6):397-408. PubMed ID: 25058177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer's epigenetic drugs: where are they in the cancer medicines?
    Ghasemi S
    Pharmacogenomics J; 2020 Jun; 20(3):367-379. PubMed ID: 31819161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic opportunities and challenges in cancer.
    Best JD; Carey N
    Drug Discov Today; 2010 Jan; 15(1-2):65-70. PubMed ID: 19897050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.
    Zahan T; Das PK; Akter SF; Habib R; Rahman MH; Karim MR; Islam F
    Anticancer Agents Med Chem; 2020; 20(18):2190-2206. PubMed ID: 32748758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs.
    Baker EK; Johnstone RW; Zalcberg JR; El-Osta A
    Oncogene; 2005 Dec; 24(54):8061-75. PubMed ID: 16091741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors.
    Madkour MM; Ramadan WS; Saleh E; El-Awady R
    Ann Med; 2023 Dec; 55(1):2203946. PubMed ID: 37092854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic Regulation Towards Acquired Drug Resistance in Cancer.
    Ketkar M; Dutt S
    Subcell Biochem; 2022; 100():473-502. PubMed ID: 36301503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.